Incidences of rare blood clot in four U.S residents after J&J COVID-19 vaccine shots, has urged the country to halt the administration of these vaccines for a temporary time period. This has also produced a delay in roll out of Johnson and Johnson vaccines to Europe.
In fact, South Africa has also reportedly suspended the use of these vaccines, following the cases of rare blood clot in the United States.
Reports have it that the move comes after the European regulators declared, this month, that they have allegedly found a potential link between AstraZeneca’s COVID-19 vaccine and a similar rare blood clotting issue that led to a small number of fatalities in the region.
Acting Commissioner at U.S Food and Drug Administration, Janet Woodcock mentioned that the organization estimates the pause to be a matter of days and is aimed at offering information to healthcare experts on how to detect and treat the clots.
Meanwhile, FDA official, Peter Marks commented that J&J blood clot cases were quite similar to the AstraZeneca cases. Marks added that there, however, are no such cases among recipients of Pfizer/BioNTech or Moderna vaccines as these use a different technology and are being administered to a majority of the U.S population.
As per credible reports, J&J’s vaccine rollout in the country has been limited by production issues. As of April 13, about 7.2 million doses of the J&J vaccines have been administered in the United States compared with 185 million of the other two.
Importantly, an advisory committee to the U.S. CDC is expected to meet on Wednesday to evaluate and study the clotting cases, while also raising votes on recommendations for future use of the shot. Post this, the FDA would then review the analysis.
Post this announcement, J&J’s shares went down by 1.6%. Moreover, the company is also working closely with regulators and taking down notes on relationship between the clots and its vaccine.